Masy Pharma: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Masy Pharma
Largest movements
- Receivables within one year +€127,334
up €127,334 (+55.5%), from €229,333 to €356,667
of which Trade receivables: +€104,411
- Stocks and contracts +€19,279
up €19,279 (+8.1%), from €236,652 to €255,931
- Other debts +€117,317
up €117,317 (+122,691%), from €96 to €117,412
- Trade debts +€19,421
up €19,421 (+27.1%), from €71,547 to €90,968
- Gross operating margin -€22,145
down €22,145 (-15.8%), from €140,007 to €117,862
- Staff costs -€13,678
down €13,678 (-12.1%), from €112,603 to €98,925
- Taxes +€5,733
up €5,733, from -€3,090 to €2,642
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €559,238 | €700,251 | +€141,013 | +25.2% |
| Fixed assets | 21/28 | €18,840 | €13,645 | -€5,195 | -27.6% |
| Tangible fixed assets | 22/27 | €17,931 | €12,735 | -€5,195 | -29.0% |
| Furniture and vehicles | 24 | €17,931 | €12,735 | -€5,195 | -29.0% |
| Financial fixed assets | 28 | €910 | €910 | = | 0.0% |
| Current assets | 29/58 | €540,398 | €686,606 | +€146,208 | +27.1% |
| Stocks and contracts in progress | 3 | €236,652 | €255,931 | +€19,279 | +8.1% |
| Stocks | 30/36 | €236,652 | €255,931 | +€19,279 | +8.1% |
| Amounts receivable within one year | 40/41 | €229,333 | €356,667 | +€127,334 | +55.5% |
| Trade receivables | 40 | €111,125 | €215,537 | +€104,411 | +94.0% |
| Other amounts receivable | 41 | €118,208 | €141,130 | +€22,923 | +19.4% |
| Current investments | 50/53 | €0 | - | = | |
| Cash at bank and in hand | 54/58 | €62,837 | €63,849 | +€1,012 | +1.6% |
| Deferred charges and accrued income | 490/1 | €11,577 | €10,159 | -€1,417 | -12.2% |
| Total equity and liabilities | 10/49 | €559,238 | €700,251 | +€141,013 | +25.2% |
| Equity | 10/15 | €469,775 | €475,544 | +€5,768 | +1.2% |
| Contributions | 10/11 | €18,592 | €18,592 | = | 0.0% |
| Reserves | 13 | €451,183 | €456,952 | +€5,768 | +1.3% |
| Tax-exempt reserves | 132 | €2,975 | €2,975 | = | 0.0% |
| Distributable reserves | 133 | €448,209 | €453,977 | +€5,768 | +1.3% |
| Profit (loss) carried forward | 14 | €0 | - | = | |
| Amounts payable | 17/49 | €89,463 | €224,707 | +€135,245 | +151% |
| Amounts payable within one year | 42/48 | €86,119 | €217,049 | +€130,929 | +152% |
| Trade debts | 44 | €71,547 | €90,968 | +€19,421 | +27.1% |
| Suppliers | 440/4 | €71,547 | €90,968 | +€19,421 | +27.1% |
| Taxes, remuneration and social security | 45 | €14,477 | €8,668 | -€5,809 | -40.1% |
| Taxes | 450/3 | €0 | - | = | |
| Remuneration and social security | 454/9 | €14,477 | €8,668 | -€5,809 | -40.1% |
| Other amounts payable | 47/48 | €96 | €117,412 | +€117,317 | +122,691% |
| Accrued charges and deferred income | 492/3 | €3,343 | €7,659 | +€4,315 | +129% |
| Remuneration, social security and pensions | 62 | €112,603 | €98,925 | -€13,678 | -12.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €5,212 | €5,195 | -€17 | -0.3% |
| Other operating charges | 640/8 | €4,175 | €4,009 | -€167 | -4.0% |
| Gross operating margin | 9900 | €140,007 | €117,862 | -€22,145 | -15.8% |
| Operating profit (loss) | 9901 | €18,017 | €9,733 | -€8,284 | -46.0% |
| Financial income | 75/76B | €1,561 | €1,044 | -€516 | -33.1% |
| Recurring financial income | 75 | €1,561 | €1,044 | -€516 | -33.1% |
| Financial charges | 65/66B | €3,552 | €2,367 | -€1,185 | -33.4% |
| Recurring financial charges | 65 | €3,552 | €2,367 | -€1,185 | -33.4% |
| Profit (loss) for the period before taxes | 9903 | €16,026 | €8,411 | -€7,615 | -47.5% |
| Income taxes | 67/77 | -€3,090 | €2,642 | +€5,733 | |
| Profit (loss) for the period | 9904 | €19,116 | €5,768 | -€13,348 | -69.8% |
| Profit (loss) for the period to be appropriated | 9905 | €19,116 | €5,768 | -€13,348 | -69.8% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 17 October 2026 via checked.be.